《大行報告》摩通上調康方生物-B(09926.HK)目標價至60元 評級「增持」
摩根大通發表報告指,康方生物-B(09926.HK)旗下「卡度尼利單抗」去年銷售達5.46億元人民幣,表現強勁,雖然受到疫情的影響,但仍超出預期和公司指引。此外,公司預料今年全年增長20%至30%。
該行因應公司去年業績表現更新其模型預測,長期銷售預測基本保持不變,同時適當提高毛利率假設,因旗下凱得寧(AK104)的毛利表現強勁,但部分被公司繼續投資產品線和新產品的營運支出增加所抵銷。
摩通又上調康方生物股份目標價,由58元升至60元,評級維持「增持」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.